Anti-AKT1 (phospho T308 + S473) antibody (ab66134)
- Product nameAnti-AKT1 (phospho T308 + S473) antibodySee all AKT1 primary antibodies ...
- DescriptionRabbit polyclonal to AKT1 (phospho T308 + S473)
- SpecificityThe motif corresponding to the major autophosphorylation site of the human AKT1 kinase protein. This antibody does not cross react to the non-phosphorylated AKT1 or with other unrelated phosphorylated serine.
- Tested applicationsIHC-P, ELISA, WB, IP, Dot Blot more details
- Species reactivityReacts with: Mouse, Rat, Cow, Human, Xenopus laevis, Moloney Murine Leukemia Virus, Culex pipiens
Synthetic peptide within Human AKT1 (phospho T308). The exact sequence is proprietary.
- Positive control
- PDGF stimulated 3T3 whole cell lysate
- Storage instructionsStore at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
- Storage bufferPreservative: 0.05% Proclin
Constituents: 1% BSA, PBS, pH 7.2
- Concentration information loading...
- PurityProtein A purified
- Purification notesSite-directed adsorption and epitope affinity purification.
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab66134 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||IHC-P: Use a concentration of 1 - 2 µg/ml.|
|ELISA||ELISA: Use a concentration of 0.01 - 0.1 µg/ml.|
|WB||WB: Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 60 kDa.|
|IP||IP: Use a concentration of 2 - 5 µg/ml.|
|Dot Blot||Dot: 1/2000.|
- FunctionPlays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.
- Tissue specificityExpressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.
- Involvement in diseaseDefects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).
- Sequence similaritiesBelongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 PH domain.
Contains 1 protein kinase domain.
- DomainBinding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
The AGC-kinase C-terminal mediates interaction with THEM4.
modificationsPhosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells.
Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.
- Cellular localizationCytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.
- Entrez Gene: 280991 Cow
- Entrez Gene: 207 Human
- Entrez Gene: 11651 Mouse
- Entrez Gene: 24185 Rat
- Entrez Gene: 399170 Xenopus laevis
- Omim: 164730 Human
- SwissProt: Q01314 Cow
- SwissProt: P31749 Human
- SwissProt: P31750 Mouse
- SwissProt: P47196 Rat
- SwissProt: Q98TY9 Xenopus laevis
- Unigene: 525622 Human
- Unigene: 6645 Mouse
- Unigene: 11422 Rat
- Unigene: 738 Xenopus laevis
- AKT 1 antibody
- AKT antibody
- AKT1 antibody
- AKT1_HUMAN antibody
- C AKT antibody
- MGC9965 antibody
- MGC99656 antibody
- Oncogene AKT1 antibody
- PKB antibody
- PKB-ALPHA antibody
- PRKBA antibody
- Protein Kinase B Alpha antibody
- Protein kinase B antibody
- Proto-oncogene c-Akt antibody
- RAC Alpha antibody
- RAC antibody
- RAC PK Alpha antibody
- RAC Serine/Threonine Protein Kinase antibody
- RAC-alpha serine/threonine-protein kinase antibody
- RAC-PK-alpha antibody
- vAKT Murine Thymoma Viral Oncogene Homolog 1 antibody
Anti-AKT1 (phospho T308 + S473) antibody images
All lanes : Anti-AKT1 (phospho T308 + S473) antibody (ab66134) at 1/1000 dilution
Lane 1 : PDGF stimulated 3T3cells
Lane 2 : PDGF stimulated 3T3 cells with Band abolished by pre-incubation with immunizing peptide.
Predicted band size : 60 kDa
1 µg of a peptide was blotted onto a nitrocellulose membrane followed by ab66134 at 1/2000 dilution. Upper Panel: Dot 1: AKT1(pT308) peptide, Dots 2,3,4: unrelated phosphopeptides. Lower Panel: Dot 1: non phosphopeptide AKT1, Dots 2,3,4: unrelated non-phosphopeptides.
References for Anti-AKT1 (phospho T308 + S473) antibody (ab66134)
This product has been referenced in:
- Shen R et al. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Cancer Lett 339:135-43 (2013). Read more (PubMed: 23887057) »
- Thrush AB et al. A single prior bout of exercise protects against palmitate-induced insulin resistance despite an increase in total ceramide content. Am J Physiol Regul Integr Comp Physiol 300:R1200-8 (2011). WB ; Rat . Read more (PubMed: 21325642) »